My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Veracyte, Inc. - Common Stock (NQ:VCYT)

35.77 +0.62 (+1.76%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Cathie Wood's Ark Invest Buys Over $92M Worth Of ProShares Bitcoin ETF, Sells Coinbase, Block And Palantir Shares ↗

December 27, 2023

On Wednesday, Cathie Wood-led Ark Invest made a significant move in the cryptocurrency space, purchasing over $92 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO).

Via Benzinga

Topics ETFs

Are You A Trader Or Investor: Biotech Momentum Is Picking Up ↗

November 20, 2023

ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market.

Via Talk Markets

Topics ETFs

Veracyte: Q3 Earnings Insights ↗

November 07, 2023

Via Benzinga

7 Undervalued Stocks That Analysts Love Right Now ↗

October 26, 2023

With many investors concerned about what may lie ahead in the market, these potentially de-risked undervalued stocks may be ideal.

Via InvestorPlace

Veracyte Stock Is Volatile After-Hours - Here's Why ↗

October 04, 2023

Veracyte, Inc. (NASDAQ: VCYT) shares are volatile after-hours on Wednesday after the company announced that new data from a phase 3 trial validates the value of the Decipher Prostate Genomic Classifier...

Via Benzinga

Here's Why This Little-Known Growth Stock Is a Buy ↗

May 22, 2023

Analysts think this genomic test maker could have major upside in the next year.

Via The Motley Fool

Looking Into Veracyte's Return On Capital Employed ↗

May 17, 2023

Via Benzinga

Recap: Veracyte Q1 Earnings ↗

May 04, 2023

Via Benzinga

Earnings Scheduled For November 7, 2023 ↗

November 07, 2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.

Via Benzinga

The Latest Analyst Ratings for Veracyte ↗

October 20, 2023

Via Benzinga

Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors? ↗

September 02, 2023

The genetic test maker is rapidly increasing test volumes.

Via The Motley Fool

Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom ↗

July 08, 2023

AI is changing the face of biotechnology and drug discovery. Don't miss out on the next big boom in biotech, here are 3 stocks to consider.

Via InvestorPlace

Market Mixes It Up With A Broad Rally ↗

June 05, 2023

Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive.

Via Talk Markets

Time To Play Small Cap Life Science Stocks ↗

May 15, 2023

The overall market sentiment has been hit hard by MACRO concerns. The dominating narrative is the Fed and the Debt Ceiling.

Via Talk Markets

Something Happened In Biotech Last Week ↗

May 08, 2023

Biotech stocks were more constructive last week with some sharp moves up.

Via Talk Markets

A Preview Of Veracyte's Earnings ↗

February 21, 2023

Via Benzinga

Expert Ratings for Veracyte ↗

January 05, 2023

Via Benzinga

Earnings Scheduled For May 4, 2023 ↗

May 04, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.

Via Benzinga

Biotech And Life Science Trades: Q1 2023 Performance By The Numbers ↗

April 01, 2023

Despite a strong month and a great finish to the quarter, many traders remain cautious about the market. It’s been a volatile time after the collapse of Silicon Valley Bank, but the first quarter of...

Via Talk Markets

7 Biotech Stocks That Could Be the Next Big Thing ↗

March 15, 2023

Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough.

Via InvestorPlace

Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors? ↗

March 10, 2023

This diagnostics test maker has held up well over the last year.

Via The Motley Fool

SMID Cap Life Science Update: Are You An Investor Or Trader? ↗

February 20, 2023

Despite choppy trading, there is an upward tilt to life science stocks since the 9/26/22 lows.

Via Talk Markets

When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader? ↗

February 05, 2023

A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?

Via Talk Markets

Better Long-Term Buy in 2023: Exact Sciences or Veracyte? ↗

January 24, 2023

As cancer screenings are becoming covered more often, both companies stand to gain.

Via The Motley Fool

Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock ↗

January 18, 2023

Via Benzinga

Earnings Scheduled For February 22, 2023 ↗

February 22, 2023

Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023 ↗

January 18, 2023

Via Benzinga

This Small-Cap Stock Is a No-Brainer Buy ↗

January 18, 2023

This genomic test maker's stock was beaten down in 2022. But it could be heading for a rebound this year.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

Veracyte Stock Showing Market Leadership; Earns 93 RS Rating ↗

December 01, 2022

Veracyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.